Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease

/PRNewswire/ -- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid...

Related Keywords

Temple University ,Pennsylvania ,United States ,Michigan ,Philadelphia ,Catherine Radovich ,Robin Schmidt ,Ryan Zeidan ,Adam Daley ,Peter Bojo ,Ronald Dadino ,Prnewswire Sling Therapeutics Inc ,Bellevue University ,Michigan Institute For Clinical ,Life Sciences Innovation ,Novartis ,University Of Michigan ,Therapeutics Inc ,Health Research ,Rise Fund ,Regulatory Affairs ,Massachusetts Institute Of Technology ,Drug Administration ,California Institute Of Technology ,University Of The Sciences ,Berry Company Public Relations ,Management Team ,Sling Therapeutics ,Chief Executive Officer ,Astellas Pharma ,Investigational New Drug ,Sciences Innovation ,Lucian Iancovici ,Managing Director ,Rise Funds ,Chief Executive ,Millendo Therapeutics ,Massachusetts Institute ,California Institute ,Chief Operating ,Vice President ,Michigan Institute ,Healthcare Management ,Pharmaceutical Quality Assurance ,Treatment Modality ,Thyroid Eye Disease ,Clinical Endocrinology ,